Israel - English - Ministry of Health

neopharm scientific ltd - eribulin as mesilate - solution for injection - eribulin as mesilate 0.44 mg/ml - eribulin - halaven is indicated for the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.halaven is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.

Israel - English - Ministry of Health

neopharm scientific ltd - romidepsin - powder and diluent for solution for injection - romidepsin 10 mg/vial - romidepsin - romidepsin - • treatment of cutaneous t-cell lymphoma (ctcl) in patients who have received at least one prior systemic therapy.• treatment of peripheral t-cell lymphoma (ptcl) in patients who have received at least one prior therapy.

Israel - English - Ministry of Health

neopharm scientific ltd - paclitaxel - powder for dispersion for infusion - paclitaxel 100 mg/vial - paclitaxel - abraxane monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated. abraxane in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. abraxane in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.

Israel - English - Ministry of Health

neopharm scientific ltd - paclitaxel - powder for suspension for infusion - paclitaxel 100 mg/vial - paclitaxel - abraxane monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated. abraxane in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. abraxane in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.

Israel - English - Ministry of Health

neopharm scientific ltd - pomalidomide - hard capsule - pomalidomide 1 mg - pomalidomide - imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide

Israel - English - Ministry of Health

neopharm scientific ltd - pomalidomide - hard capsule - pomalidomide 1 mg - pomalidomide - imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide

Israel - English - Ministry of Health

neopharm scientific ltd - pomalidomide - hard capsule - pomalidomide 1 mg - pomalidomide - imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide

Israel - English - Ministry of Health

neopharm scientific ltd - pomalidomide - hard capsule - pomalidomide 1 mg - pomalidomide - imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide

Israel - English - Ministry of Health

neopharm scientific ltd - pomalidomide - hard capsule - pomalidomide 1 mg - pomalidomide - imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide

Israel - English - Ministry of Health

neopharm scientific ltd - pomalidomide - hard capsule - pomalidomide 2 mg - pomalidomide - imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide